Acrivon Therapeutics

Revenue and free cash flow have no predictability at this stage. Clinical milestones are the primary drivers, with a prespecified interim analysis for the serous all‑comer arms slated for the second half of 2026 and Phase 3 readiness targeted by mid‑2026. Competitive and regulatory risks remain elevated, and timelines are subject to change.

This profile is the opposite of the toll‑booth economics we prefer for long‑term compounding.